Abstract
Bisantrene solubility and skin toxicity were studied in mice given intraperitoneal (IP) and intradermal (ID) drug respectively. Bisantrene (1 mg/ml) in 5% dextrose readily precipitated in the mouse peritoneum. The admixture of bisantrene into various lipophilic solvents did not reduce drug precipitation in vivo in the mouse or in vitro in human plasma at 37 degrees C. Drug stability studies using high performance liquid chromatography (HPLC) showed markedly reduced bisantrene stability at alkaline pH. Bisantrene skin toxicity in BALB/c mice was characterized by ulceration which persisted for up to four months after ID injection. Skin toxicity was consistently reduced by dilute sodium bicarbonate injection into the bisantrene extravasation site. Three clinical extravasation cases treated with sodium bicarbonate showed no bisantrene ulceration. Ineffective local antidotes included sodium cromolyn, N-acetylcysteine, hydrocortisone, and heat (which appeared to increase toxicity).
MeSH Terms
Aged
Animals
Anthracenes/adverse effects,therapeutic use,toxicity
Antibiotics, Antineoplastic/adverse effects,therapeutic use,toxicity
Bicarbonates/therapeutic use
Chromatography, High Pressure Liquid/methods
Clinical Trials as Topic
Drug Incompatibility
Drug Stability
Erythema/chemically induced,drug therapy
Female
Humans
Hydrogen-Ion Concentration
Male
Mice
Mice, Inbred BALB C
Mice, Inbred DBA
Skin Ulcer/drug therapy
Sodium Bicarbonate
Solubility
Chemicals
Anthracenes
Antibiotics, Antineoplastic
Bicarbonates
bisantrene
Sodium Bicarbonate
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Dorr R T
Peng Y M
Alberts D S
References (9)
9 references, click to expand
-
Experimental model of doxorubicin extravasation in the mouse.
J Pharmacol Methods. 1980 Nov;4(3):237-50
PMID: 7442269
-
Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Cancer Res. 1983 Feb;43(2):925-9
PMID: 6848203
-
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Cancer Res. 1982 Mar;42(3):1170-5
PMID: 7037174
-
Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
Cancer Res. 1982 Jan;42(1):354-8
PMID: 7053862
-
Activity of 9-10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Leads for phase II trials in man.
Cancer Chemother Pharmacol. 1981;6(2):141-4
PMID: 7307232
-
The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse.
Cancer Chemother Pharmacol. 1980;5(1):17-20
PMID: 7460191
-
High performance liquid chromatography of a new anticancer drug, ADCA--physicochemical properties and pharmacokinetics.
Life Sci. 1981 Jul 27;29(4):361-9
PMID: 7278493
-
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.
Cancer Chemother Rep. 1966 May;50(4):219-44
PMID: 4957125
-
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Cancer Res. 1981 Aug;41(8):3118-21
PMID: 6265075